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A 22-year-old Asian male presented with fever, non-productive cough, right-sided pleuritic chest pain
and was found to have a large right hydropneumothorax. A chest tube was placed. Pleural ﬂuid analysis
revealed a lymphocytic predominant exudate and he was subsequently started on four-drug daily anti-
tuberculosis therapy (isoniazid, ethambutol, rifampin, pyrazinamide). Pleural biopsy revealed acid-fast
bacilli. Given his persistent pleural effusion, he was given four doses of intrapleural tissue plasmin-
ogen activator (tPA) and dornase alpha (DNase) via his chest tube over a period of 6 days resulting in
clinical and radiologic improvement. Pleural biopsy and pleural ﬂuid culture specimens later revealed
Mycobacterium tuberculosis. Intrapleural tPA-DNase therapy has demonstrated improved resolution of
infections and shortened hospitalizations for parapneumonic infectious effusions. However, there is little
literature on the use of intrapleural ﬁbrinolytics speciﬁcally for pleural tuberculosis associated effusions.
Furthermore, the American Thoracic Society does not comment on therapeutic thoracentesis or intra-
pleural ﬁbrinolytic therapy in their recommendations for treatment of pleural tuberculosis. In our case of
pleural TB-associated hydropneumothorax, the use of intrapleural tPA-DNase therapy facilitated pleural
ﬂuid drainage and resulted in near-complete resolution of the effusion.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pleural tuberculosis (TB) is rare. The most recent epidemiologic
study in 2003 reported 14,874 US TB cases of which 20.4% were
exclusively extra-pulmonary. Of these patients, 18.5% reported
pleura as the major site of disease. From 1993 to 2003, pleural TB
comprised only 3.9% of all US TB cases [1]. Globally there is sig-
niﬁcant geographical variation, for example the incidence in Spain
is nearly six times that of the US [2].
Little published data exists about the management of pleural TB
associated effusions. We report a case of an Asian male with a large
hydropneumothorax found to have acid-fast bacilli (AFB) on pleuralFB, acid fast bacilli; HD, hos-
minase; INH, isoniazid; EMB,
Jefferson University Hospital,
, USA.
owan).
Ltd. This is an open access article ubiopsy and ultimatelyMycobacterium tuberculosis in pleural biopsy
and ﬂuid cultures.2. Case report
A 22 year-old Asian male smoker presented with ten days of
non-productive cough, subjective fevers, night sweats, right-sided
pleuritic chest pain and increasing dyspnea. One week prior to
presentation, he was empirically treated for pneumonia with lev-
oﬂoxacin without improvement. The patient was an exchange
student from China whose last visit home was two months prior to
presentation to our facility. Both of the patient's parents had been
diagnosed with TB before his birth with unclear treatment status.
The patient's physical examwas remarkable for decreased right-
sided breath sounds. Vital signs were: temperature, 98.4 F; heart
rate, 102/min, regular; BP, 102/58 mm Hg; respiratory rate, 28/min;
oxygen saturation, 95% on room air.
Chest radiograph (CXR) showed a large right hydro-
pneumothorax and right upper lobe inﬁltrate with scarring (Fig. 1).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Initial chest radiographs of patient upon presentation. A, Posteroanterior view showing large right hydropneumothorax. B, Lateral view showing hydropneumothorax.
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gency department (Fig. 2A). A chest computed tomography scan
showed tree-in-bud nodularity in the right upper lobe, possible
consolidation in the right lower lobe and calciﬁed hilar lymph-
adenopathy. Additionally, there were foci of gas in the right-sided
hydropneumothorax which could have represented a loculated
component. Due to imaging ﬁndings suggesting prior granuloma-
tous infection and patient history, there was high suspicion for TB
and on airborne precautions were instituted.
A pleural drainage catheter was placed into the hydro-
pneumothorax. Analysis of the pleural ﬂuid obtained from this
procedure revealed: pH, 7.70; glucose, 11 mg/dL; protein, 4.5 g/L;
LDH, 1458 units/L; WBC, 1340 cells/mL (64% lymphocytes); RBC,
4000 cells/mL; adenosine deaminase (ADA), 57.5 units/L. Addition-
ally, serum protein was 5.6 g/L.
Throughout his hospitalization, the patient had multiple AFB
smears and cultures performed (2 concentrated sputum, 2 pleural
ﬂuid, 1 bronchoalveolar lavage), which were negative. A pleural
biopsy demonstrated 1þ AFB on smear and necrotizing granulo-
matous inﬂammation. The patient was started on an anti-
tuberculosis regimen (isoniazid (INH) 300 mg, ethambutol (EMB)
800 mg, rifampin (RIF) 450 mg and pyrazinamide (PZA) 1000 mg)
because of his ﬁndings of a lymphocyte predominant exudative
pleural effusion, AFB positive pleural biopsy with necrotizing
granulomatous inﬂammation and history of exposure to TB.
Given the persistent pleural effusion, he was given four doses of
tissue plasminogen activator (tPA) and dornase alfa (DNase)
instilled via the chest tube over a period of 6 days resulting inFig. 2. Chest radiographs showing resolution of the hydropneumothorax. Aimproved drainage and clinical and radiologic improvement
(Table 1, Fig. 2B). Fibrinolytic therapy was terminated at the point of
near complete resolution of the pleural effusion as evidenced by
CXR. The chest tube was removed and the patient was discharged
on hospital day 13. Two weeks after discharge, a follow-up CXR
demonstrated a persistent small right-sided effusion, however; the
patient was asymptomatic (Fig. 3). Ultimately, the pleural ﬂuid and
biopsy cultures were positive for Mycobacterium tuberculosis.
3. Discussion
Tuberculous pleuritis should be considered in patients with a
lymphocyte-predominant exudative effusion. The etiology of an
effusion can be difﬁcult to classify and often requires both pleural
ﬂuid analysis and clinical correlation [3]. Our patient had a pleural
ﬂuid protein/serum protein ratio of 0.80 and elevated pleural ﬂuid
LDH indicating an exudate. Low pleural ﬂuid glucose (40 mg/dL)
narrowed our differential to rheumatoid pleurisy, empyema, ma-
lignancy, lupus pleuritis or tuberculous pleurisy [4]. In this patient,
serum protein >4 g/dL made tuberculous pleural effusion more
likely [5]. Our patient's pleural ﬂuid did not show the typical pH of
<7.30 as seen in most tuberculous effusions [6]. In one meta-
analysis, the average pH for tuberculous effusions was 7.18 [7].
The pleural ﬂuid ADA value was found to be elevated at 57.5 U/L.
The ADA assay has a sensitivity of 92% and a speciﬁcity of 90 for
diagnosing TB pleurisy [8].
The best diagnostic approach to suspected tuberculous pleuritis
is debated. The yield of pleural ﬂuid smears is 10% and of pleural, Following chest tube placement. B, Day 4 after chest tube placement.
Table 1
Dosages of intrapleural ﬁbrinolytic therapy and resultant chest tube outputs.
Dose number 1 (HD#3) 2 (HD#4) 3 (HD#6) þ DNase 4 (HD#9) þ DNase
Dose 10 mg tPA in 30 ml 0.9% NaCl 10 mg tPA in 30 ml 0.9% NaCl 10 mg tPA in 30 ml 0.9%
NaCl þ 5 mg DNase in 30 ml sterile water
10 mg tPA in 30 ml 0.9% NaCl þ 5 mg
DNase in 30 ml sterile water
Chest tube output 170 mL 1100 mL 1600 mL 815 mL
Legend: HD ¼ hospital day.
Fig. 3. Chest radiographs at patient's two-week follow-up visit. A, Posteroanterior view. B, Lateral view.
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granulomas or (þ) culture has diagnostic yields ranging from 55 to
93% [1,9]. Evaluation for TB with thoracentesis plus closed pleural
biopsy has a 95% sensitivity, which is roughly on par withTable 2
Studies utilizing intrapleural infusions in treatment of tuberculous pleural effusions.
Author e
year
Study design Patients, N Therapy
Cases
Viedma
et al.
[22]
2006
Randomized,
prospective
29 Group 1: intrapleural urokinase (125,000 U
via intrathoracic tube repeated every 12
hours until quantity of pleural ﬂuid <50 cm
(n ¼ 12); Group 2: simple drainage with
suction (n ¼ 17)
Chung et al.
[15]
2008
Double blind,
randomized,
placebo-
controlled
64 Group 1: free-ﬂowing effusions irrigated wi
50 mL saline (n ¼ 20); Group 2: loculated
effusions
irrigated with 250,000 IU streptokinase
(n ¼ 22);
Group 3: loculated effusions irrigated with
saline
(n ¼ 22)
Therapy performed for 3 consecutive days f
all
groups
Park et al.
[20]
1996
Case series 31 TB
(n ¼ 21)
When drainage <100 ml/day, 250,000 IU
urokinase
in 250 ml 0.9% NaCl divided into 80 ml
aliquots and
performed until drainage <50 ml/day
Kwak et al.
[21]
2004
Randomized,
prospective
43 Group 1: control group, anti-tuberculous
agents
alone (n¼ 22); Group 2: 100,000 IU urokina
dissolved in 150 ml of normal saline daily v
a pig-
tail catheter until drainage <50 ml/day
(n ¼ 21)thoracoscopy [10]. Diagnostic modalities with highest yield are
slow to show results making acute workup difﬁcult.
The American Thoracic Society recommends a 6-month regimen
for treatment of pleural TB consisting of a 2-month period of INH,Endpoints Conclusion
I)
3
Residual pleural thickening,
amount of pleural ﬂuid drained
Urokinase lessens residual pleural
thickening, increases ﬂuid drainage
th
or
Followed for 12 months: clinical
symptoms, radiologic effusion, lung
function, residual pleural
thickening, effusion volume
removed
Streptokinase improves resolution of
effusion, lessens residual pleural
thickening, accelerates recovery of
pulmonary function in loculated
effusions
Radiographic appearance, ﬂuid
drainage
Urokinase not effective in effusions
with honeycomb appearance or when
parietal pleura >5 mm thickness
se
ia
Residual pleural thickening Urokinase reduces residual pleural
thickening
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Corticosteroids have not reduced residual pleural thickening and
are not recommended [11,12]. Therapeutic thoracentesis is not
discussed in the guidelines and is controversial, however it is
usually performed if a patient is more than mildly symptomatic
[13]. Signiﬁcantly less residual pleural thickening and accelerated
recovery of pulmonary function has been seen in patients who
received therapeutic thoracentesis for TB associated effusions
[14,15]. However, other studies have concluded that residual
pleural thickening is not inﬂuenced by this intervention [16]. Other
drawbacks to thoracentesis include risk of transmission to health
providers, bleeding, and pulmonary injury. In our patient's clinical
situation a chest tube was placed on presentation for symptomatic
relief.
Treatment of parapneumonic infectious effusions is comprised
of antibiotic therapy and early pleural drainage [17]. A small per-
centage of these patients require additional therapy. The MIST-1
(Multi-Center Intrapleural Sepsis Trial) did not demonstrate any
improvement in patient mortality, rate of surgery, or the length of
the hospital stay with use of intrapleural tPA therapy alone [18].
However, the use of intrapleural tPA-DNase therapy in the MIST-2
trial resulted in improved resolution of infection, shortened hos-
pitalization, and resolved effusion in 95% of patients without the
need for surgery [19]. Unfortunately, none of the patients in the
MIST-1 and MIST-2 trials had isolates of TB recovered making
applicability to our case difﬁcult.
A literature review on use of intrapleural tPA-DNase therapy in
tuberculous pleural effusions has shown that this therapy improves
ﬂuid drainage and lessens residual pleural thickening (Table 2)
[15,20e22]. However, there is little literature on the use of intra-
pleural ﬁbrinolytics speciﬁcally for pleural TB associated effusions.
In our case of pleural TB-associated hydropneumothorax, the use of
intrapleural tPA-DNase therapy facilitated pleural ﬂuid drainage
and resulted in near-complete resolution of the effusion. Further
studies examining the impact of intrapleural lytic therapy on cost,
length of stay and patient outcomes in tuberculous effusions are
necessary.
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